Exhibit 99.1 PASSAGE BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2023 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS PHILADELPHIA – March 4, 2024 – Passage Bio, Inc. (Nasdaq: PASG), a clinical- stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided recent business highlights. "In 2023, we achieved a significant milestone by announcing encouraging ...